Ketogenesis instigates immune suppression in enzalutamide resistant prostate cancer via OTUD7B β-hydroxybutyrylation
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Haoran Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China; Institute of Urology, Wenzhou M…. Hauptthemen laut MEDLINE: Benzamides, Prostatic Neoplasms, Castration-Resistant, Drug Resistance, Neoplasm, Phenylthiohydantoin. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: Zhejiang Medical Association, Pioneer and Leading Goose R&D Program of Zhejiang, Wenzhou Medical University.
Abstract (Originalsprache)
Next-generation androgen receptor inhibitors are the primary treatment for metastatic prostate cancer. Unfortunately, the majority of patients rapidly develop resistance. Resistance to enzalutamide has been linked to the emergence of an immunosuppressive tumor, although the underlying mechanisms remain poorly understood. In this study, we observed a marked overexpression of enzymes involved in the ketogenic pathway in enzalutamide-induced castration-resistant prostate cancer, which contributed to immune desertification and resistance to immunotherapy. Mechanistically, upregulation of the ketogenic pathway led to the accumulation of β-hydroxybutyrate, which promoted β-hydroxybutyrylation of the cell cycle-regulated deubiquitinase OTUD7B at lysine 511. This modification impaired the degradation of APC/C substrates, resulting in a subsequent reduction in cytoplasmic double-stranded DNA accumulation, thereby attenuating cGAS-STING activation and interferon expression. These findings shed light on the metabolic adaptations and immune escape driven by androgen receptor signaling inhibitors, potentially informing the development of more effective and durable therapeutic approaches in the near future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China; Institute of Urology, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China; Zhejiang Key Labo…
- Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
- Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China; Institute of Urology, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
- Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China; Institute of Urology, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China; Translational Med…
- Center for Wound Repair and Regeneration, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, 200000, China.
Förderung
- Zhejiang Medical Association
- Pioneer and Leading Goose R&D Program of Zhejiang
- Wenzhou Medical University
- Zhejiang Provincial Traditional Chinese Medicine Scientific Research Fund
- Wenzhou Municipal Science and Technology Bureau
- Natural Science Foundation of Zhejiang Province
- Zhejiang Province Natural Science Foundation
- Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Jiang, H., Zeng, Y., Ning, W., Hong, J., Zhu, M., Li, P., Ye, F., Chen, Z., Chen, H., Chen, W., Li, G., & Huang, H. (2025). Ketogenesis instigates immune suppression in enzalutamide resistant prostate cancer via OTUD7B β-hydroxybutyrylation. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217808
Vancouver
Jiang H, Zeng Y, Ning W, Hong J, Zhu M, Li P, et al. Ketogenesis instigates immune suppression in enzalutamide resistant prostate cancer via OTUD7B β-hydroxybutyrylation. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217808
BibTeX
@article{Jiang2025,
author = {Jiang, Haoran and Zeng, Yuan and Ning, Weiqiang and Hong, Junkai and Zhu, Moyang and Li, Ping and Ye, Fangdie and Chen, Zhifa and Chen, Haoran and Chen, Wei and Li, Gang and Huang, Hang},
title = {Ketogenesis instigates immune suppression in enzalutamide resistant prostate cancer via OTUD7B β-hydroxybutyrylation},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217808}
}
EUVIMED